SEC Filing Summary: 180 Life Sciences Corp. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by 180 Life Sciences Corp. (formerly KBL Merger Corp. IV) on December 23, 2020, covering events occurring on December 17 and 18, 2020. The company is an emerging growth company incorporated in Delaware, with common stock (ATNF) and warrants (ATNFW) trading on The NASDAQ Stock Market LLC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of two directors from the Board of Directors:
- Shoshana Shendelman, Ph.D.: Resigned effective December 17, 2020, due to potential conflicts of interest between her board position and other endeavors.
- Prof. Richard W. Barker, MA, D.Phil, OBE: Resigned effective December 18, 2020, due to other commitments preventing sufficient time for company matters.
The company explicitly states that neither resignation was connected to a disagreement regarding the company's operations, policies, or practices.
Outlook and Management Commentary
Management has announced an immediate search for qualified replacements for the two departing directors. The former directors expressed wishes for the company's future success. No specific financial guidance, risk factors, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the timeline for appointing new directors to replace Dr. Shendelman and Prof. Barker.
- Confirm the current composition of the Board of Directors following these resignations.
- Review subsequent filings for any financial updates, as this 8-K contains no financial data.
- Monitor for any further disclosures regarding the "potential conflicts of interest" cited by Dr. Shendelman.